Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)
SAN DIEGO, CA and SOUTH SAN FRANCISCO, CA / / January 21, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ('Dermata') and Revance Therapeutics, Inc. (Nasdaq: RVNC) ('Revance' together ...
Pharmaceutical Technology23d
Incobotulinumtoxin A by Merz Therapeutics for Unspecified Musculoskeletal Disorders: Likelihood of Approval
Incobotulinumtoxin A is indicated for the treatment of adults with cervical dystonia to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naïve and previously ...
i24d
The long Covid ‘treatments’ to avoid
Into that void have sprouted many competing hypotheses about the biology of long Covid, as well as connected ideas about potential treatments. But most theories are still at an early scientific stage.
Frontiers25d
Efficacy and safety of camrelizumab for the treatment of cervical cancer: a systematic review and meta-analysis
Table 4. Comparison of outcomes between Camrelizumab and Pembrolizumab in the treatment of cervical cancer. Since the advent of immunotherapy, considerable attention has been devoted to the compliance ...
The Straits Times29d
The new tech treatments that could improve mental health
Irene Jimenez Padilla used to suffer persistent traumatic flashbacks from her time as a nurse during the Covid-19 pandemic. Then a cult computer puzzle game changed everything. Ms Padilla was ...
eLife29d
Monitoring of Cell-free Human Papillomavirus DNA in Metastatic or Recurrent Cervical Cancer: Clinical Significance and Treatment Implications
HPV cfDNA is a promising tumor marker for HPV+ cervical cancer that offers advantages over SCC-Ag. In the context of precision medicine, HPV cfDNA is poised to play an increasingly pivotal role in ...